Ignite Creation Date:
2025-12-24 @ 3:59 PM
Ignite Modification Date:
2026-03-13 @ 3:22 PM
Study NCT ID:
NCT02595892
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-08-26
First Post:
2015-11-03
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Sponsor:
National Cancer Institute (NCI)
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2016-08-25
Start Date Type:
ACTUAL
Primary Completion Date:
2020-06-15
Primary Completion Date Type:
ACTUAL
Completion Date:
2026-08-05
Completion Date Type:
ESTIMATED
First Submit Date:
2015-11-03
First Submit QC Date:
None
Study First Post Date:
2015-11-04
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2022-06-13
Results First Submit QC Date:
None
Results First Post Date:
2022-10-25
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-08-06
Last Update Post Date:
2025-08-26
Last Update Post Date Type:
ESTIMATED